Clinical Trial Update: Open-label Extension Study of Brazikumab in Crohn's Disease [Phase 3]

View source ↗

Summary

An open-label extension of Brazikumab in Crohn's Disease (Phase 3) has been terminated, with results posted on 2026-04-01.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Inflammatory Bowel Disease

Drugs mentioned

• Brazikumab

Snippet

Sponsor: AstraZeneca | Conditions: Crohn's Disease, IBD | Phase 3 | Status: TERMINATED | Results posted: 2026-04-01